fepblue glp 1 coverage Medicaid of and Spending on GLP-1s FEP Blue update to PA

The clinical spectrum of MASLD spans from simple steatosis, which is often benign and potentially reversible, to metabolic dysfunction-associated steatohepatitis (MASH), a progressive and inflammatory condition that may lead to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) (2, 3)

& Panda, S

A meaningful percentage of patients who are either overweight or obese have at least one of these comorbidities

Success in developing these approaches could transform the clinical utility of peptide therapeutics by eliminating the need for injection

At 7.5 mg (75 units at 10 mg/mL): Side effects tend to be milder at this increase if you tolerated 5 mg well